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Summary
 
Anti-DNA antibodies are regulated in normal individuals but are found in high concentration
in the serum of systemic lupus erythematosus (SLE) patients and the MRL lpr/lpr mouse
model of SLE. We previously studied the regulation of anti–double-stranded (ds)DNA and
anti–single-stranded (ss)DNA B cells in a nonautoimmune background by generating mice car-
rying immunoglobulin transgenes coding for anti-DNAs derived from MRL 
 
lpr/lpr
 
. Anti-
dsDNA B cells undergo receptor editing, but anti-ssDNA B cells seem to be functionally
silenced. Here we have investigated how anti-DNA B cells are regulated in recombination-
activating gene (RAG)-2
 
2/2
 
 mice. In this setting, anti-dsDNA B cells are eliminated by apop-
tosis in the bone marrow and anti-ssDNA B cells are partially activated.
Key words: anti-DNA antibody • B cell deletion • B cell anergy • recombination-activating 
gene deﬁciency • apoptosis
 
A
 
striking feature of Lupus is that individual SLE patients
express unique subsets of the many anti-nuclear anti-
bodies (ANAs)
 
1
 
 seen in the population of individuals with
this disease (1). As pointed out by Hardin (2), these idio-
syncratic spectra of ANAs would not be expected by non-
specific activation of the repertoire and suggest instead that
autoantibodies arise by immunization. The oligoclonal na-
ture of autoantibodies and the evidence for positive selec-
tion of somatic mutants of autoantibodies provides support
for this notion (3, 4). Craft and Hardin (5) also noted that
these subsets of ANAs include antibodies to “physically-
linked epitopes”, e.g., anti-DNA with antihistone(s). They
interpreted such linked sets to mean that the activating an-
tigen must be a nucleoprotein particle. An elegant exten-
sion of this insight is the demonstration that the blebs on
the surface of apoptotic cells contain the targets of Lupus
autoantibodies such as DNA, Ro, La, and ribonucleopro-
tein and could thereby be the delivery vehicles of self-anti-
gen (6).
The observation that self-antigens activate autoreactive B
cells in disease implies that such B cells are normally under
active, negative regulation. Indeed, B cells specific for both
facultative and constitutive self-antigens have been shown
to be deleted or inactivated (7–10). The exact site and stage
of these manifestations of tolerance have been obscured by
receptor editing, a process that rescues autoreactive B cells
by revising their receptors (11–16). It has been possible to
study deletion directly in mice that are either unable to edit
(SCID or recombination-activating gene [RAG]
 
2/2
 
) or
lack a substrate for editing (H or L chain–deficient mice)
(17–20). Mature B cells can be generated by crossing H and
L chain transgenes onto either RAG
 
2/2
 
 or SCID mice.
These immunodeficient mice can then delete or arrest au-
toreactive B cells, and thereby provide a powerful tool for
studying tolerance in the absence of rearrangement.
We have generated transgenic (tg) mice expressing anti-
DNA antibodies characteristic of those found in autoim-
mune disease (10). In this study we have crossed these anti–
double-stranded (ds)DNA (3H9RVk4) and anti-ssDNA
(3H9RVk8) tg mice onto RAG-2
 
2
 
/
 
2
 
 mice. This model al-
lows us to determine whether anti-DNA B cells are deleted
by programmed cell death, whether apoptotic cells present
the immunogens that drive DNA-specific B cells, and
whether negative regulation of these autospecificities is sus-
tained in the absence of T cells. We find that in RAG-2
 
2/2
 
mice, dsDNA B cells are eliminated by apoptosis but ss-
DNA B cells appear to be activated. These data show that
deletion efficiently regulates anti-dsDNA and suggest a role
for T cells in B cell anergy but not central deletion.
 
1
 
Abbreviations used in this paper:
 
 ANA, anti-nuclear antibodies; BCR, B
cell receptor; dsDNA, double-stranded DNA; RAG, recombination-acti-
vating gene; ssDNA, single-stranded DNA; tg, transgenic.
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Materials and Methods
 
Mice.
 
The generation of 3H9 site-directed tg (3H9R), Vk4,
and Vk8 tg mice has been described previously (15, 16). All three
lines were crossed to RAG-2
 
2
 
/
 
2
 
 mice on an inbred 129/SvEv
background (Taconic Farms, Inc., Germantown, NY). 3H9R/
RAG-2
 
2/2
 
 and 3H9R mice were crossed to Vk4/RAG-2
 
2/2
 
and Vk8RAG-2
 
2/2
 
 to produce 3H9RVk4/RAG-2
 
2/2
 
 and
3H9RVk8/RAG-2
 
2/2
 
 or double tg RAG-2
 
1/2
 
 mice, respec-
tively. The genotypes of mice were determined by PCR as de-
scribed previously (15, 16). All experimental mice were 10–16 wk
of age.
 
Flow Cytometric Analysis.
 
Single-cell suspensions were pre-
pared from the bone marrow and spleen as described previously
(20). Cell staining and four-color FACS
 
Ò
 
 analysis were conducted
as described previously (20). Pro-B, pre-B, immature B, and ma-
ture B cells were visualized by incubating bone marrow and
splenic cells with a combination of FITC-S7, an antibody against
CD43 (21); allophycocyanin-6B2, an anti-B220 antibody (Phar-
Mingen, San Diego, CA); Texas red goat anti–mouse IgM
(Southern Biotechnology Associates, Inc., Birmingham, AL); and
biotin-conjugated rat anti–mouse IgD (Southern Biotechnology
Associates, Inc.). PE-streptavidin (Molecular Probes, Inc., Eu-
gene, OR) was used to reveal the biotin reagents. An anti-
dsDNA antibody, 3H9Vk4, and an antiidiotypic antibody, 1.209,
specific for various 3H9 heavy and 
 
k 
 
light chain combinations (8),
were conjugated with FITC following the manufacturer’s in-
struction (Molecular Probes). Dead cells were excluded by stain-
ing with propidium iodide and cell samples were analyzed using a
FACSvantage
 
Ò
 
 (Becton Dickinson, San Jose, CA).
 
ELISAs.
 
Igs in serum and supernatants were measured as de-
scribed previously (20). Binding to ssDNA and dsDNA was tested
by a two-step solution phase ELISA as previously described (13).
 
TUNEL (TdT-mediated dUTP Nick-end Labeling) Assay.
 
Apop-
tosis of bone marrow cells was examined using the In Situ Cell
Death Detection Kit (Boehringer Mannheim, Indianapolis, IN).
The cell suspensions were prepared following the procedures
provided by the company, except that the cells were stained with
allophycocyanin-B220 before fixation. Apoptotic cells were ana-
lyzed by flow cytometry.
 
Induction of Apoptosis and Gel Electrophoresis DNA Fragmentation
Assay.
 
Isolated splenic cells were incubated with ionomycin, a
Ca
 
2
 
1
 
 agonist (Sigma Chemical Co., St. Louis, MO), at 1 
 
m
 
g/ml
at 37
 
8
 
C overnight. Apoptosis of splenic cells was confirmed by
gel electrophoresis. DNA was prepared for gel electrophoresis as
follows: cell pellets obtained by centrifugation at 13,000 rpm for
30 s were lysed with 400 
 
m
 
l of lysis buffer containing 0.2% Triton
X-100, 10 mM Tris, and 1 mM EDTA, pH 8.0. DNA fragments
were precipitated from 200 
 
m
 
l of cell lysate with 0.5 M NaCl and
1 vol isopropanol at 
 
2
 
20
 
8
 
C overnight. DNA fragments were
washed with 70% ETOH and resuspended in 100 
 
m
 
l of water.
Electrophoresis was performed on 1% agarose gels.
 
T Cell Depletion.
 
T cells were depleted using anti-Thy 1.2
antibody (J1j10; American Type Culture Collection, Rockville,
MD) and rabbit complement (Accurate Chemical & Scientific
Co., Westbury, NY). Spleen cells were incubated with anti-Thy
1.2 (1:100) and complement (1:10) for 45 min at 37
 
8
 
C. Dead
cells were removed by centrifugation through Lympholyte-M
(Accurate Chemical & Scientific Corporation) for 20 min at
1,200 
 
g
 
 at room temperature.
 
Cell Proliferation.
 
Cell proliferation was monitored by [
 
3
 
H]
thymidine incorporation. 2 
 
3 
 
10
 
5
 
 T cell–depleted splenocytes
were cultured in 96-well microtiter plates with various doses of
LPS (0–10 
 
m
 
g/ml), IL-4 (5 
 
m
 
l/ml; R&D Systems, Minneapolis,
 
MN), and anti-IgM F(ab
 
9
 
)
 
2 
 
(0–50 
 
m
 
g/ml; Jackson ImmunoRe-
search Labs., Inc. West Grove, PA) in RPMI 1640 medium con-
taining 10% FCS for 72 h. Cells were
 
 
 
pulsed with [
 
3
 
H]thymidine
(1 
 
m
 
Ci/well) for 18 h before harvesting. Determinations were
performed in triplicate and the results are expressed as mean of
triplicate. Experiments were repeated at least three times with
one to two mice in each group.
 
Results
 
Anti-dsDNA B Cells Are Absent, but Anti-ssDNA B Cells
Mature in RAG-2
 
2
 
/
 
2
 
 Mice.
 
B cell development was as-
sessed in 3H9RVk4/RAG-2
 
2/2
 
 or 3H9RVk8/RAG-2
 
2/2
 
mice based on the expression of the cell surface markers
B220, CD43, IgM, and IgD. According to B220 and
CD43, B cell development was arrested at the pro-B cell
stage in RAG-2
 
2/2
 
 mice (B220
 
1
 
, CD43
 
low
 
), but addition
of the 3H9 heavy chain gene allowed B cells to proceed to
the pre-B cell stage (B220
 
1
 
, CD43
 
2
 
, IgM
 
2
 
; Fig. 1 
 
a
 
).
These results are similar to those in H chain tg SCID or
RAG
 
2/2
 
 mice (Table 1). The introduction of both 3H9 H
chain and Vk8 L chain genes into RAG-2
 
2/2
 
 mice com-
pletely rescued B cell development as evidenced by the
generation of surface IgM
 
1
 
IgD
 
1
 
 B cells (Fig. 1 
 
b
 
). Mature
B cells extensively populated the periphery and expressed
normal levels of sIgM (Fig. 1 
 
c
 
). These results show that
functional anti-ssDNA antibody genes are able to rescue
B cell development in RAG-2
 
2/2
 
 mice. Similar results
have been reported for 3H9Vk8 transgenes in SCID mice
(Table 1).
The H and L chain gene combination 3H9RVk4 that
codes for anti-dsDNA failed to promote full maturation of
RAG-2
 
2/2
 
 B cells. No IgM
 
1
 
 or IgM
 
1
 
IgD
 
1
 
 B cells were de-
tectable in the bone marrow (Fig. 1, 
 
a
 
 and 
 
b
 
) or spleen (Fig.
1 
 
c
 
). We assume that these anti-dsDNA B cells are deleted at
the transition from pre-B to immature B cells, at a point at
which the BCR density is below our level of detection.
 
Anti-dsDNA B Cells Are Deleted by Apoptosis.
 
To ask
whether anti-dsDNA B cells are eliminated by apoptosis,
we assayed for programmed cell death in the bone marrow
using the TUNEL (TdT-mediated dUTP nick-end label-
ing) assay. Apoptotic cells were detected at frequencies of
 
z
 
10% in RAG-2
 
2/2
 
 and 3H9RVk4/RAG-2
 
2/2
 
 mice and
4–5% in non-tg RAG
 
1
 
/
 
1
 
 and 3H9RVk8/RAG-2
 
2/2
 
 B
cells (Fig. 2). These apparently apoptotic cells had very low
levels of B220 on the surface (Fig. 2), which was neverthe-
less clearly higher than the signal given by nonspecific Ig.
Therefore, we believe that these cells are B cell precursors
and that the low level of B220 results from the membrane
changes of lymphocytes undergoing apoptosis (23, 24).
Furthermore, other bone marrow cells such as macro-
phages and stem cells are unlikely to contribute to the in-
creased apoptosis in 3H9RVk4 RAG
 
2/2
 
 tg mice.
 
The Regulation of Anti-dsDNA B Cells May Be Initiated by
Binding to Apoptotic Cells.
 
Deletion of anti-dsDNA B cells
in the bone marrow implies that the antigen(s) specific for
the 3H9RVk4 BCR is present in the bone marrow. A 
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likely source of DNA and/or DNA–protein complexes are
the blebs present on the surface of apoptotic cells (6).
Therefore, we examined the binding of 3H9Vk4 antibody
to apoptotic cells. Spleen cells were treated with ionomycin
and apoptosis was confirmed by DNA fragmentation pat-
terns (Fig. 3 
 
a
 
). 3H9Vk4 antibody bound to 
 
z
 
60% of
splenic cells incubated with ionomycin, as compared with
25% of cells without ionomycin. A control antibody of the
Figure 1. Flow cytometric analysis of B cell development. Cells from the bone marrow (a and b) and spleen (c) were resolved by four-color analysis for
surface expression of B220/CD45R, CD43/S7, IgM, and IgD. Correlative expression of CD43, B220 (a, top) and IgM (a, bottom) based on lymphocyte
gate. Cells from the B2201CD432 window of a (top) were analyzed for expression of IgM and IgD (b). Pre-B (B2201CD432IgM2), immature
B(B2201CD432IgM1IgD2), and mature B (B2201CD432IgM1IgD1) cells are shown in different quadrants. Splenic cells were analyzed with anti-B220
and anti-IgM antibodies based on lymphocyte gate (c).
Table 1. B Cell Development of tg Mice Crossed on RAG2/2 or SCID Background
RAG2/2 Specificity B cell development Reference
3H9RVk4 dsDNA Deleted at the transition from pre-B to immature B cells 20
3H9RVk8 ssDNA Mature B cells in the periphery 10
Sp6 TNP/DNA Arrested at the transition from pre-B to immature B cells 22
Anti–MHC I H-2k In H-2b background: deleted at the transition from B220hi to B220bright cells 17
In H-2d background: mature B cells in the periphery
HC186 NP Mature B cells in the periphery 18
3H9Vk8/SCID ssDNA Mature B cells in the periphery 191250 Regulation of Anti-DNA B Cells in RAG-deficient Mice
same isotype, MOPC141, did not bind to apoptotic cells
(Fig. 3 b). These results are similar to those observed for
SLE sera specific for DNA, Ro, and La antigens (6).
We also examined the binding of 3H9Vk4 antibody to
bone marrow cells of various mice. We found that
3H9Vk4 antibody bound to z14% of bone marrow cells
from RAG-22/2, but to only 1% of bone marrow cells
from RAG-21/2 mice (Fig. 3 c). The binding of 3H9Vk4
antibody to bone marrow cells was also high in 3H9RVk4/
RAG-22/2 mice (z13%, data not shown). The comparable
level of apoptosis in RAG-22/2 and 3H9RVk4/RAG-22/2
bone marrow suggests that autoreactive B cells in 3H9RVk4/
RAG-22/2 mice are deleted by apoptosis.
Anti-ssDNA B Cells Do Not Secrete Antibodies In Vivo.
RAG-22/2 mice with anti-ssDNA transgenes (3H9RVk8)
have nearly normal numbers of B cells. All these B cells are
idiotype positive, as demonstrated by the reaction with 1.209
antibody specific for the 3H9 heavy chain paired with a k
light chain (Fig. 4). These peripheral B cells do not secrete
antibody as 3H9RVk8/RAG-22/2 mice have 100–500-fold
lower levels of serum Ig than do normal mice (Fig. 5).
To understand the status of these B cells, we analyzed
splenic cells for additional markers. Staining with anti-IgM
and anti-IgD showed two populations of B cells, IgMhi-
IgDlo and IgMloIgDhi B cells, in 3H9RVk8/RAG-22/2
mice, but only IgMloIgDhi B cells in 3H9RVk8/RAG-21/2
mice (Fig. 6, top). The extra IgMhiIgDlo population in the
RAG-22/2 mice may either be activated B cells (25) or
maturation-blocked B cells (26). To distinguish these alter-
natives, CD43 expression of the IgMhiIgDlo B cells was ex-
amined. CD43 is expressed on pro-B cells and activated B
cells (27), but not mature resting B cells (28). We found
that IgMhiIgDlo B cells express high levels of CD43 (IgMlo
IgDhi B cells had the characteristic low level of CD43) (Fig.
6, bottom). Thus, we can define two populations of B cells
in 3H9RVk8/RAG-22/2 mice. One population consists of
activated B cells as defined by high expression of IgM and
CD43, but low IgD (IgMhiIgDloCD43hi), and a second
population consists of B cells with no CD43, low IgM, but
high IgD (IgMloIgDhiCD432). Few, if any, of the activated
B cells are found in 3H9RVk8/RAG-21/2 mice or in
non-tg littermates (Fig. 6).
Are Anti-ssDNA B Cells from RAG-22/2 and RAG-21/2
Mice Functional? We measured the response of 3H9RVk8
B cells to LPS and found that cells from both 3H9RVk8/
RAG-21/2 and 3H9RVk8/RAG-22/2 mice responded to
Figure 2. Analysis of apop-
totic cells in the bone marrow by
flow cytometry. Bone marrow
cells were stained with anti-B220
antibody and fixed with 2%
paraformaldehyde. Apoptotic
cells were labeled and detected
using the In Situ Cell Death De-
tection Kit (Boehringer Mann-
heim). The numbers shown rep-
resent the percentage of
apoptotic cells in the upper right
and lower right quadrants.
Figure 3. Binding of 3H9Vk4 antibody to apoptotic cells. (a) DNA
fragmentation of apoptotic cells. DNA from freshly isolated splenocytes
(lane 1) and cells cultured overnight in the presence of ionomycin (lane 2)
was electrophoresed in 1% agar gel. Ionomycin-treated cells show DNA-
fragmentation typical of apoptotic cells. (b) Binding of 3H9Vk4 antibody
to apoptotic cells. Ionomycin-treated (bold line) and fresh (broken line)
spleen cells were incubated with FITC-labeled 3H9Vk4 antibody (left)
and the isotype-matched control antibody MOPC141 (right) and analyzed
by flow cytometry. (c) Binding of 3H9Vk4 antibody to bone marrow
cells. Bone marrow cells of RAG-22/2 (bold line) and control RAG-21/2
(broken line) were isolated, stained with FITC-3H9Vk4 antibody (left) and
MOPC 141 (right), and analyzed by flow cytometry.
Figure 4. Staining of B cells with antiidiotype antibody 1.209. Spleno-
cytes were stained with the combinations of anti-IgM and antiidiotype
1.209. Lymphocytes were gated for analysis.
Figure 5. Production of immunoglobulins in 3H9RVk4/RAG-22/2
(s) and 3H9RVk8/RAG-22/2 mice (e). Total serum IgM (A) and IgG
(B) were determined by ELISA as described in Materials and Methods and
compared to normal mice (h).1251 Xu et al.
LPS stimulation in a dose-dependent manner (Fig. 7 a), but
3H9RVk8/RAG-22/2 B cells are hyperresponsive to LPS
relative to non-tg RAG-21/2 B cells. This hyperactivity
may be derived from the “activated” B cells seen in vivo.
B cells from 3H9RVk8/RAG-21/2 mice had a reduced
response to low doses of LPS (Fig. 7 a), consistent with the
idea that these B cells are anergic. The difference between
RAG-21/2 and RAG-22/2 mice may reflect the presence
or absence of T cells. We studied the possible influence of
T cells by addition of IL-4 to our in vitro proliferation as-
say. Proliferation of B cells in response to a submitogenic
concentration of LPS (0.1 mg/ml) was enhanced by IL-4 in
3H9RVk8/RAG-22/2 mice (Fig. 7 c), indicating that an
IL-4–mediated signal was capable of acting in synergy with
LPS. 3H9RVk8/RAG-21/2 B cells responded poorly to
low doses of LPS even in the presence of IL-4. The failure
of IL-4 to promote 3H9RVk8/RAG-21/2 B cell prolifera-
tion in synergy with LPS supports the view that these B
cells have a defect in response to LPS and that this defect
cannot be overcome by this T cell–derived cytokine.
We also tested the proliferative response of 3H9RVk8 B
cells to anti-IgM. 3H9RVk8 B cells from RAG-22/2 mice
showed a better response to anti-IgM cross-linking than
did those from non-tg RAG-21/1 mice, providing further
evidence for in vivo activation of these anti-ssDNA B cells.
Surprisingly, B cells from 3H9RVk8/RAG-21/2 mice re-
sponded as well as non-tg RAG-21/1 mice to anti-IgM
stimulation (Fig. 7 b). Why 3H9RVk8/RAG-21/2 B cells
have a normal response to anti-IgM cross-linking, but an
impaired response to LPS is unclear.
In addition, we determined the effect of IL-4 on B cell
proliferation stimulated by anti-IgM. In all three mouse
lines, the combination of anti-IgM and IL-4 induced a
strong proliferative response that was greater than the sum
of that induced by either stimulus alone (Fig. 7 c). This sug-
gests that the 3H9RVk8 B cells have an intact signal trans-
duction pathway through both their Ig and IL-4 receptors.
Discussion
It is generally accepted that of the pool of progenitor B
cells, only a few B cells manage to mature and the rest die
at various stages of development. Yet it has been difficult to
actually detect apoptotic B cells in the bone marrow, prob-
ably because of rapid phagocytosis of dying cells by mac-
rophages (29). Recently, cell death has been detected at
different stages of B lineage differentiation when precursor
B cell proliferation is perturbed, as in Em-myc tg (30) and
SCID (31) mice. Presumably, phagocytosis cannot keep
pace with the rate of cell death in these cases. In keeping
with these findings, we detect elevated levels of apoptosis
in the bone marrow of RAG-22/2 mice. RAG-22/2 B cell
development is arrested at the pro-B stage (Fig. 1), but why
cell death should occur at this stage is not known.
Rearrangement and H chain expression is one of the re-
quirements for entry into cell cycle and survival of these
cells, and indeed, crossing heavy and light chain transgenes
into RAG2/2 mice rescues B cell development (17, 18) and
reduces apoptosis to wild-type levels (Fig. 2). On the other
hand, autoantibody tgs have a limited capacity for restoring
functional B cells in RAG2/2 mice. 3H9RVk4 transgenes
advance B cell development to the B2201CD432IgM2
pre-B stage, but immature B cells (B2201, IgM1) are unde-
Figure 6. FACSÒ profile of splenocytes from 3H9RVk8/RAG-22/2
mice. Spleen cells were labeled with anti-B220, anti-IgM, anti-IgD, and
anti-CD43 antibodies, and gated B2201 cells were analyzed. Cells were
then displayed in IgM versus IgD blots and gated for IgMloIgDhi (G1, solid
line) and IgMhiIgDlo (G2, broken line) in the upper panel. Either cell popu-
lation was then analyzed for CD43 expression in the lower panel.
Figure 7. Proliferation of B cells
in response to LPS and anti-IgM in
absence and presence of IL-4. 2 3
105 T-depleted splenocytes from
non-tg (h), 3H9RVk8/RAG-21/2
(n), and 3H9RVk8/RAG-22/2
(s) mice were cultured in the
presence of various doses of LPS
(A) and anti-IgM (B) for 72 h. B
cells (2 3 105 T cell–depleted
splenic cells) were also cultured
with submitogenic concentration
of LPS (0.1 mg/ml) or anti-IgM (1
mg/ml) in the presence or absence
of IL-4 (5 mg/ml) for 72 h (C). Cells were pulsed with [3H]thymidine (1 mCi/well) for 18 h before harvesting. Data shown are the average of triplicate
determinations and are representative of at least three different experiments.1252 Regulation of Anti-DNA B Cells in RAG-deficient Mice
tectable. For this autospecificity, a B cell early in the transi-
tion from pre-B to immature B cell appears to be the target
for deletion, and consequently the level of apoptosis in
3H9RVk4/RAG-22/2 mice is as high as in RAG-22/2
mice. We assume that the expression of the self-reactive
IgM on the cell surface initiates signaling events that result
in apoptosis. The fact that we cannot detect appreciable
levels of IgM or B220 on the apoptotic TUNEL-positive
cells — even though they are immature B cells — might be
due to membrane disintegration and concomitant loss of
cell surface molecules during the apoptotic process (23, 24).
A second model for anti-DNA–reactive B cells is the Sp6
tg mouse. Here the anti-TNP/DNA cross-reactive B cells
are also deleted at the pre-B to immature B transitional
stage (22). Such a short survival time of immature B cells
predicts a narrow time window for editing in anti-dsDNA
B cells. Indeed, we find that editing in 3H9RVk4 B cells is
predominantly on the targeted allele, suggesting that these
cells have time for only a few rearrangement attempts (32).
Dying cells display the intracellular targets of SLE au-
toantibodies (e.g., DNA, Ro, and La) on their surface as
shown by the binding of antibody from SLE sera to the
blebs on the surface of apoptotic cells (6). Hence, apoptosis
in the bone marrow deletes self-reactive B cells and
provides an abundant source of autoantigens. We have
shown that 3H9Vk4 mAb binds to apoptotic cells in spleen
and bone marrow. The close proximity between dying
3H9RVk4 cells and immature 3H9RVk4 B cells may ex-
plain the efficient regulation of this autoreactivity. This
may also explain why anti-DNA B cells appear to be de-
leted at an earlier B cell maturation stage than anti-HEL or
anti-H2 B cells. The nature of the antigens and the way
they are presented to B cells could account for the differ-
ences in B cell regulation. Membrane antigens (H-2 and
HEL) are presumably distributed evenly on the cell surface.
Their interaction with BCR may transduce a moderate sig-
nal strong enough to induce editing but not strong enough
to initiate an immediate cell death process. These cells may
need a more prolonged signal through the BCR to induce
the death pathway and therefore are deleted at the imma-
ture to mature B cell transition (7, 8, 33). The DNA-con-
taining antigens are presented in the blebs with a high local
concentration, which may cause strong local cross-linking
of BCRs. This type of interaction may deliver a signal for
both editing and deletion. Successful editing within a lim-
ited time period may rescue the B cells from the apoptotic
pathway. Alternatively, a protective mechanism may have
to insure stringent regulation against such harmful autoanti-
gens as dsDNA, e.g., a second type of signal delivered to
the B cells during the DNA–BCR interaction.
The anti-ssDNA transgenes, 3H9RVk8, rescue B cell
development on the RAG-22/2 background, but yield un-
expected results with regard to the phenotype of these cells.
About 40% of B cells in the spleen of the tg RAG-22/2 ex-
press high levels of IgM and CD43 and low levels of IgD, a
phenotype associated with activated B cells (27). In vitro
proliferation assays also reveal a B cell population from
3H9RVk8/RAG-22/2 mice that is hyperactive when stim-
ulated with LPS or LPS and IL-4. Taking these two obser-
vations together, we conclude that there is a population
(IgMhiCD43hiIgDlow) that has been activated in vivo and it
is this self-primed population that has an accelerated prolif-
erative response in vitro. These B cells do not secrete au-
toantibodies in vivo, but that is explainable by the absence
of secondary activation signals from T cells. Thus, even
though the cells are hyperactive in some assays they are not
fully activated for Ig production.
3H9RVk8/RAG-21/2 mice contain few if any B cells
with an activation phenotype. Rather they are anergic. We
show that they are hyporesponsive to LPS stimulation,
whereas strong IgM cross-linking with intact anti-IgM an-
tibody results in normal proliferation of the tg B cells. Sim-
ilar results have been obtained by Nguyen et al. (34) using
conventional VH3H9/Vk8 tg mice. Proliferation to LPS
Figure 8. A model for the regulation of
anti-DNA B cells. Pre-B cells that have
functional rearranged heavy and light chain
genes express surface IgM that can bind to
autoantigens. The strong IgM cross-linking
by dsDNA from blebs of apoptotic cells in-
duces secondary rearrangement (receptor
editing) and altered binding specificity.
Anti-dsDNA B cells that fail to edit their re-
ceptors (e.g., in the absence of RAG) die
via apoptosis. These dying cells provide an
enriched source of autoantigens to anti-ds-
DNA B cells. Weaker IgM cross-linking by
ssDNA allows the B cells to mature and
populate the periphery with an activated
phenotype. We propose that these activated
B cells are subsequently inactivated or elim-
inated by T cell–dependent mechanism(s).1253 Xu et al.
and suboptimal IgM cross-linking with anti-IgM F(ab)92
antibody were reduced, whereas IgM cross-linking in the
presence of T help was normal in most animals (34). Inter-
estingly, the VH3H9/Vk8 anti-ssDNA anergic B cells dif-
fer from anti-HEL B cells that are exposed to soluble HEL
(9). The latter show a 20-fold reduction of surface IgM (9),
whereas the overall IgM levels in conventional and site-
directed 3H9/Vk8 tg B cells were similar to non-tg litter-
mates (Fig. 6, reference 34). This finding might also explain
the normal Ca21 flux in the VH3H9/Vk8 mice (34), com-
pared with transient Ca21 flux in anti-HEL/soluble HEL
double tg mice (35). In addition, anti-HEL B cells have a
shortened life span in the presence of soluble HEL (36),
whereas anti-ssDNA B cells live as long as non-tg B cells
(34). In summary, it appears that B cell tolerance not only
consists of the two distinct stages of deletion and anergy,
but that qualitative differences also exist in the level of an-
ergy. These differences are probably due to variations in
the strength and/or quality of antigen–BCR interactions
(as discussed earlier for deletion). What mechanism(s) are
responsible for the anergy induction? Goodnow (37) dis-
cussed that B cell anergy may be induced by (a) the en-
counter with self-antigen early in development (clonal an-
ergy), (b) interaction with antigen-specific regulatory T
cells, or (c) regulatory elements of an idiotype network (37).
Our data clearly favor the hypothesis that regulatory T cells
silence self-reactive B cells, since self-reactive 3H9RVk8 B
cells in RAG-22/2 mice are activated rather than anergized.
We presume that the “self” milieu of all mice is similar,
although quantitative difference are apparent in tg or mu-
tant mice (see Fig. 2) and self-activated B cells are likely to
be a feature of all mice, not just RAG-22/2 tgs. How then
do normal mice inactivate 3H9RVk8 or other self-reactive
B cells? T cells seem the most likely regulator and the acti-
vated status of B cells exposed to antigens at early stages of
development may be the target for regulatory T cells. How
T cells affect B cell anergy (or accelerated cell death) and
whether direct suppression by cell–cell contact occurs or
soluble factors produced by T cells are involved is not
known. Furthermore, the phenotype of regulatory T cells
is also unclear. TCR-g/d cells seem to downregulate the
autoimmune process in MRL mice since TCR-g/d–defi-
cient mice show a much more severe disease (38). In the
system of organ-specific autoimmunity, e.g., after neonatal
thymectomy, CD41 IL-2R1 cells (which probably express
TCR-a/b) prevent autoimmunity (39). Although it seems
likely that the regulatory T cells are activated by the same
autoantigen as the self-reactive B cells, the question of
specificity of regulatory T cells in either organ-specific or
systemic autoimmunity has not yet been resolved. In addi-
tion, future work will have to address if B cells become an-
ergized by one single event (antigen–B cell interaction/an-
tigen–B cell–T cell interaction) of if they must constantly
receive anergizing signals.
In summary, we propose the following model for B cell
selection (Fig. 8): B cells that are unable to express a BCR
die by apoptosis at the pre-B cells stage (RAG-22/2 mice).
The expression of a functional BCR allows maturation to
immature B cells. As soon as IgM is expressed on the cell
surface it can receive signals due to antigen binding. If this
is a strong binding resulting in a strong signal, then receptor
editing is initiated. If a cell continues to express a self-reac-
tive receptor (either because it can not be directly edited in
case of a conventional tgs or because the BCR is still au-
toreactive after editing), the amount of signal will increase
and induce apoptosis. Cells that manage to revise their
BCR will be released from the death signal and continue to
mature. If such mature B cells then encounter antigen in
the periphery, they will be stimulated to produce antibody.
Alternatively, if B cells bind self-antigen weakly, they will
receive a qualitatively different signal that results in cell ac-
tivation rather than editing/deletion. Such activated B cells
persist in the periphery of T cell–deficient mice, but are an-
ergized by regulatory T cells in RAG-competent mice.
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